Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)
DOI:
https://doi.org/10.2340/actadv.v104.40946Keywords:
Psoriasis, Real-world, Registry, TildrakizumabAbstract
Real-world data on the effectiveness and safety of tildrakizumab, an interleukin 23p19 inhibitor, in Switzerland is limited. The objectives of this analysis were to assess the effectiveness and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis in Switzerland. Twenty-eight adults from the Swiss Dermatology Network for Targeted Therapies registry (SDNTT), who were on tildrakizumab treatment and had at least 3 months’ follow-up, were enrolled in this prospective, multicentre study. No missing data imputation was performed. The median Psoriasis Area and Severity Index (PASI) decreased from 9.5 at baseline to 2.1 and 0.3 (both p < 0.001) after 3 and 18 months, respectively, of tildrakizumab treatment. After 3 months, 76.9%/30.8% patients reached an absolute PASI < 3/ < 1. These rates increased to 85.7%/57.1% after 18 months of treatment. The proportions of patients achieving PASI 90/100 responses were 47.8%/30.4% at month 6 and 42.9%/14.3% at month 18. A significant improvement in quality of life up to 18 months of follow-up was observed as measured by the Dermatology Life Quality Index. There were no treatment discontinuations due to adverse events. This real-world registry provides robust evidence supporting the long-term effectiveness and favourable safety profile of tildrakizumab in treating patients with moderate-to-severe psoriasis.
Downloads
References
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet 2021; 397: 1301-1315.
https://doi.org/10.1016/S0140-6736(20)32549-6 DOI: https://doi.org/10.1016/S0140-6736(20)32549-6
Sharma A, Upadhyay DK, Gupta GD, Narang RK, Rai VK. IL-23/Th17 axis: a potential therapeutic target of psoriasis. Curr Drug Res Rev 2022; 14: 24-36.
https://doi.org/10.2174/2589977513666210707114520 DOI: https://doi.org/10.2174/2589977513666210707114520
Wu M, Dai C, Zeng F. Cellular mechanisms of psoriasis pathogenesis: a systemic review. Clin Cosmet Investig Dermatol 2023; 16: 2503-2515.
https://doi.org/10.2147/CCID.S420850 DOI: https://doi.org/10.2147/CCID.S420850
Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 2020; 34: 2461-2498.
https://doi.org/10.1111/jdv.16915 DOI: https://doi.org/10.1111/jdv.16915
Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021; 35: 281-317.
https://doi.org/10.1111/jdv.16926 DOI: https://doi.org/10.1111/jdv.16926
Blauvelt A, Chiricozzi A, Ehst BD, Lebwohl MG. Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review. Adv Ther 2023; 40: 3410-3433.
https://doi.org/10.1007/s12325-023-02568-0 DOI: https://doi.org/10.1007/s12325-023-02568-0
Xu S, Zhang X, Pan M, Shuai Z, Xu S, Pan F. Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis. Int Immunopharmacol 2019; 75: 105841.
https://doi.org/10.1016/j.intimp.2019.105841 DOI: https://doi.org/10.1016/j.intimp.2019.105841
Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017; 390: 276-288.
https://doi.org/10.1016/S0140-6736(17)31279-5 DOI: https://doi.org/10.1016/S0140-6736(17)31279-5
Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol 2021; 185: 323-334.
https://doi.org/10.1111/bjd.19866 DOI: https://doi.org/10.1111/bjd.19866
Egeberg A, Jullien D, Gaarn Du Jardin K, Thaçi D. Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest. J Dermatolog Treat 2023; 34: 2220447.
https://doi.org/10.1080/09546634.2023.2220447 DOI: https://doi.org/10.1080/09546634.2023.2220447
Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: Results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol 2023; 37: 85-92.
https://doi.org/10.1111/jdv.18572 DOI: https://doi.org/10.1111/jdv.18572
Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M. Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study. Clin Cosmet Investig Dermatol 2023; 16: 529-536.
https://doi.org/10.2147/CCID.S402183 DOI: https://doi.org/10.2147/CCID.S402183
Tsianakas A, Kirsch A, Petri M. Sustained efficacy and safety of tildrakizumab over 2 years in patients with moderate to severe plaque psoriasis in routine clinical practice: interim results in week 100 from the non-interventional, prospective, multicenter study TILOT. Presented at the 32 European Academy of Dermatology and Venereology (EADV) Congress, 11 - 14 October 2023, Berlin, Germany:Abstract 3110.
Burlando M, Maul JT, Salvi I, Simic D, Cozzani E, Ak M, et al. Psoriasis patients' characteristics associated with high PASI response to tildrakizumab: an international dual center study. Eur Rev Med Pharmacol Sci 2022; 26: 6772-6776.
Maul JT, Augustin M, Sorbe C, Conrad C, Anzengruber F, Mrowietz U, et al. Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study. Br J Dermatol 2021; 185: 1160-1168.
https://doi.org/10.1111/bjd.20387 DOI: https://doi.org/10.1111/bjd.20387
Cazzaniga S, Anzengruber F, Augustin M, Boehncke WH, Borradori L, Conrad C, et al. Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. J Eur Acad Dermatol Venereol 2019; 33: 2313-2318.
https://doi.org/10.1111/jdv.15983 DOI: https://doi.org/10.1111/jdv.15983
Drach M, Papageorgiou K, Maul JT, Djamei V, Yawalkar N, Häusermann P, et al. Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT). Arch Dermatol Res 2019; 311: 753-760.
https://doi.org/10.1007/s00403-019-01945-6 DOI: https://doi.org/10.1007/s00403-019-01945-6
Anzengruber F, Augustin M, Radtke MA, Thaci D, Yawalkar N, Streit M, et al. Smoking does not alter the therapy response to systemic anti-psoriatic therapies: a two-country, multi-centre, prospective, non-interventional study. Acta Derm Venereol 2019; 99: 871-877.
https://doi.org/10.2340/00015555-3221 DOI: https://doi.org/10.2340/00015555-3221
Maul JT, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. J Eur Acad Dermatol Venereol 2019; 33: 700-708.
https://doi.org/10.1111/jdv.15324 DOI: https://doi.org/10.1111/jdv.15324
Jungo P, Maul JT, Djamei V, von Felten S, Kolios AGA, Czernielewsk J, et al. Superiority in quality of life improvement of biologics over conventional systemic drugs in a Swiss Real-Life Psoriasis Registry. Dermatology 2016; 232: 655-663.
https://doi.org/10.1159/000455042 DOI: https://doi.org/10.1159/000455042
Maul JT, Djamei V, Kolios AGA, Meier B, Czernielewski J, Jungo P, et al. Efficacy and survival of systemic psoriasis treatments: an analysis of the Swiss Registry SDNTT. Dermatology 2016; 232: 640-647.
https://doi.org/10.1159/000452740 DOI: https://doi.org/10.1159/000452740
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
https://doi.org/10.1111/j.1365-2230.1994.tb01167.x DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol 2020; 182: 605-617.
https://doi.org/10.1111/bjd.18232 DOI: https://doi.org/10.1111/bjd.18232
Drerup KA, Seemann C, Gerdes S, Mrowietz U. effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology 2022; 238: 615-619.
https://doi.org/10.1159/000519924 DOI: https://doi.org/10.1159/000519924
Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of psoriasis and comorbid diseases: a narrative review. Front Immunol 2022; 13: 880201.
https://doi.org/10.3389/fimmu.2022.880201 DOI: https://doi.org/10.3389/fimmu.2022.880201
Buja A, Miatton A, Cozzolino C, Brazzale AR, Lo Bue R, Mercuri SR, et al. The prevalent comorbidome at the onset of psoriasis diagnosis. Dermatol Ther (Heidelb) 2023; 13: 2093-2105.
https://doi.org/10.1007/s13555-023-00986-0 DOI: https://doi.org/10.1007/s13555-023-00986-0
Costanzo A, Llamas-Velasco M, Fabbrocini G, Cuccia A, Rivera-Diaz R, Gaarn Du Jardin K, et al. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. J Eur Acad Dermatol Venereol 2023; 37: 2004-2015.
https://doi.org/10.1111/jdv.19229 DOI: https://doi.org/10.1111/jdv.19229
Becher G, Conner S, Ingram JA, Stephen KE, McInnes AC, Heald AH, et al. A retrospective real-world study of the effectiveness and tolerability of tildrakizumab in uk adults with moderate-to-severe chronic plaque psoriasis. Dermatol Ther (Heidelb) 2022; 12: 2343-2354.
https://doi.org/10.1007/s13555-022-00800-3 DOI: https://doi.org/10.1007/s13555-022-00800-3
Belinchón Romero I, Dauden E, Ferrándiz Foraster C, González-Cantero Á, Carrascosa Carrillo JM. Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. Ann Med 2021; 53: 1727-1736.
https://doi.org/10.1080/07853890.2021.1986637 DOI: https://doi.org/10.1080/07853890.2021.1986637
Amatore F, Villani AP, Tauber M, Viguier M, Guillot B, Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie). French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol 2019; 33: 464-483.
https://doi.org/10.1111/jdv.15340 DOI: https://doi.org/10.1111/jdv.15340
Gisondi P, Talamonti M, Chiricozzi A, Piaserico S, Amerio P, Balato A, et al. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations. Dermatol Ther (Heidelb) 2021; 11: 235-252.
https://doi.org/10.1007/s13555-020-00475-8 DOI: https://doi.org/10.1007/s13555-020-00475-8
Treatment Guidelines - International Psoriasis Council [Internet]. 2022 [cited 2023 Dec 12]. Available from: https://psoriasiscouncil.org/education/treatment-guidelines/
Galluzzo M, Talamonti M, Bernardini N, Chiricozzi A, De Simone C, Bonifati C, et al. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. Expert Opin Biol Ther 2022; 22: 1585-1592.
https://doi.org/10.1080/14712598.2022.2090835 DOI: https://doi.org/10.1080/14712598.2022.2090835
Mastorino L, Susca S, Megna M, Siliquini N, Quaglino P, Ortoncelli M, et al. Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatol Ther 2022; 35: e15378.
https://doi.org/10.1111/dth.15378 DOI: https://doi.org/10.1111/dth.15378
Daniele SG, Eldirany SA, Damiani G, Ho M, Bunick CG. Structural Basis for p19 Targeting by Anti-IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis. JID Innov 2024; 4: 100261.
https://doi.org/10.1016/j.xjidi.2024.100261 DOI: https://doi.org/10.1016/j.xjidi.2024.100261
Strober B, Ferris L, Callis Duffin K, Janak JC, Sima AP, Eckmann T, et al. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. J Am Acad Dermatol 2024; 90: 82-90.
https://doi.org/10.1016/j.jaad.2023.08.097 DOI: https://doi.org/10.1016/j.jaad.2023.08.097
Kokolakis G, Kreis G, Falqués M, Aparici M, Sondermann W. High tolerability, favorable safety, and subjects' preference for a single 200 mg/2 mL tildrakizumab injection: a phase i, open-label, randomized crossover trial in healthy volunteers. Dermatol Ther (Heidelb) 2022; 12: 2135-2144.
https://doi.org/10.1007/s13555-022-00789-9 DOI: https://doi.org/10.1007/s13555-022-00789-9
Published
How to Cite
License
Copyright (c) 2024 Julia-Tatjana Maul, Melike Ak, Sara E. Cerminara, Simona Steinmann, Elisabeth V. Goessinger, Anna Darzina, Iker Oyanguren Monferrer, Raphael Micheroli, Georgios Kokolakis, Elisabeth Roider, Felix Oestereich, Eva Mateu, Martina Burlando, Alexander A. Navarini, Thomas Kündig, Lara Valeska Maul
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
